An Exploratory Study of CS-3150 to Evaluate the Relation between Antihypertensive Effect and Baseline Factors Compared to Olmesartan Medoxomil in Patients with Essential Hypertension
Phase of Trial: Phase III
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Esaxerenone (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 15 May 2017 Status changed from active, no longer recruiting to completed.
- 14 Feb 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2017.
- 14 Feb 2017 Status changed from recruiting to active, no longer recruiting.